TY  - JOUR
AU  - Pohl, Sandra
AU  - Dimitrova, Lora
AU  - Grassow-Narlik, Maja
AU  - Jöhrens, Korinna
AU  - Acker, Till
AU  - Dohmen, Hildegard
AU  - Herms, Jochen
AU  - Dorostkar, Mario
AU  - Hartmann, Christian
AU  - Hasselblatt, Martin
AU  - Neumann, Manuela
AU  - Reifenberger, Guido
AU  - Felsberg, Jörg
AU  - Schüller, Ulrich
AU  - Zoubaa, Saida
AU  - Lorenz, Julia
AU  - Rothhammer-Hampl, Tanja
AU  - Mauch-Mücke, Katrin
AU  - Riemenschneider, Markus J.
TI  - Update on quality assurance in neuropathology: Summary of the round robin trials on TERT promoter mutation, H3-3A mutation, 1p/19q codeletion, and KIAA1549::BRAF fusion testing in Germany in 2020 and 2021
JO  - Clinical neuropathology
VL  - 42
SN  - 0722-5091
CY  - Deisenhofen, München
PB  - Dustri-Verl.
M1  - DKFZ-2023-00850
SP  - 112 - 121
PY  - 2023
AB  - We previously reported on the first neuropathological round robin trials operated together with Quality in Pathology (QuIP) GmbH in 2018 and 2019 in Germany, i.e., the trials on IDH mutational testing and MGMT promoter methylation analysis [1]. For 2020 and 2021, the spectrum of round robin trials has been expanded to cover the most commonly used assays in neuropathological institutions. In addition to IDH mutation and MGMT promoter methylation testing, there is a long tradition for 1p/19q codeletion testing relevant in the context of the diagnosis of oligodendroglioma. With the 5th edition of the World Health Organization (WHO) classification of the central nervous system tumors, additional molecular markers came into focus: TERT promoter mutation is often assessed as a molecular diagnostic criterion for IDH-wildtype glioblastoma. Moreover, several molecular diagnostic markers have been introduced for pediatric brain tumors. Here, trials on KIAA1549::BRAF fusions (common in pilocytic astrocytomas) and H3-3A mutations (in diffuse midline gliomas, H3-K27-altered and diffuse hemispheric gliomas, H3-G34-mutant) were most desired by the neuropathological community. In this update, we report on these novel round robin trials. In summary, success rates in all four trials ranged from 75 to 96
LB  - PUB:(DE-HGF)16
DO  - DOI:10.5414/NP301547
UR  - https://inrepo02.dkfz.de/record/275751
ER  -